Trial reportDrug design, development and therapy2026
Mosapride versus Metoclopramide in Critically Ill Patients with Enteral Feeding Intolerance: A Randomized, Double-Blinded Comparison.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06826443 (A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enteral feeding intolerance (EFI) from delayed gastric emptying is common in critically ill patients, leading to poor outcomes. Mosapride, a selective 5-HT4 agonist, may be a safer, more effective alternative to metoclopramide, which has limited efficacy due to tachyphylaxis and adverse effects. Objective: To compare the safety and efficacy of mosapride with metoclopramide in reducing gastric residual volume (GRV) and improving enteral nutrition delivery in intensive care unit (ICU) patients with EFI. Methods: In this prospective, randomized, double-blind, double-dummy trial, 100 mechanically ventilated ICU patients with EFI were allocated to receive either mosapride (5 mg enterally every 8 hours plus IV placebo) or metoclopramide (10 mg intravenously every 8 hours plus enteral placebo) for 7 days. GRV was measured daily via ultrasonography. Nutritional adequacy was evaluated through daily caloric and protein intake, calculated from delivered versus prescribed enteral volume. Clinical scores; including Acute Physiology and Chronic Health Evaluation (APACHE II), Sequential Organ Failure Assessment (SOFA), and the Modified Nutrition Risk in Critically Ill (mNUTRIC), as well as ICU length of stay were assessed. Adverse events were continuously monitored using a structured reporting tool. Results: The mosapride group demonstrated a more significant reduction in GRV from day 1 to day 7 (68.03% vs 39.87%, p<0.001) and higher enteral volume ratio (79.52% vs 69.48%, p<0.001). Target energy ratio was more frequently achieved in the mosapride group (86% vs 28%, p<0.001). Improvements in SOFA and mNUTRIC scores were significant only in the mosapride group. Adverse events were comparable between groups (p=0.643). ICU length of stay was non-significantly different between the two groups (p=0.051). Conclusion: Mosapride is more effective than metoclopramide in reducing GRV and enhancing enteral nutrition delivery in critically ill patients with EFI, with a favorable safety profile. These findings support its consideration as a prokinetic agent in this population. Clinical Trial Registration: NCT06826443.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.